MedTrace Logo

Iron Sucrose in Patients With Iron Deficiency and POTS

NCT04855266 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-13

No results posted yet for this study

Summary

This study aims to investigate whether the treatment of non-anemic iron deficiency with intravenous iron sucrose will result in decreased symptom reporting and improved cardiovascular indices in patients with Postural Orthostatic Tachycardia syndrome (POTS).

Conditions

  • Iron-deficiency
  • Postural Orthostatic Tachycardia Syndrome

Interventions

DRUG

Sucrose

5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted

DRUG

Placebo

Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)

DIAGNOSTIC_TEST

Tilt Table Test

A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.

Sponsors & Collaborators

Principal Investigators

  • Kamal Shouman, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2023-05-31
Completion
2023-05-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855266 on ClinicalTrials.gov